COVID-19 trials registries data warehouse

http://en.irct.ir/trial/63056

Saeid Hadi

hadiv941@mums.ac.ir

2022-06-11

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Patients over 18 years Diagnosis of clinical and laboratory signs of severe Covid-19 Body mass index above 29.9 kg per square meter based on the weight in the file Completion of the informed consent form by the patient or his / her legal guardian Severe COVID-19 patients who are admitted to the medical ICU (MICU) and will require respiratory support Patients with normal GI function who receive enteral feeding

Receive any L-carnitine supplement in the last 6 months Participate in any other research project History of liver and kidney disease Pregnancy and lactation Any allergy to L-carnitine Patients who stayed in the ICU for < 72 hours Patients who receive parenteral nutritional support Patients treated with different drug regimens from the routine ICU protocol Patients will be ongoing treatment with cisplatin, phenobarbital, phenytoin, pivalic acid, valproic acid, ifosfamide, and levetiracetam Any gastrointestinal disorders that lead to stopping enteral feeding for more than 48 hours

2

Artesh University of Medical Sciences

18

100

Iran

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

40

28 days mortality Serum level of acute phase reactive protein C Ratio of serum level of acute phase C-reactive protein to albumin ICU mortality The number of ventilator-dependent days

Phase 3

[{"arm_notes": "", "treatment_id": 720, "treatment_name": "L-carnitine", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]